Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea.
Expert Rev Neurother. 2013 Aug;13(8):883-6. doi: 10.1586/14737175.2013.820450.
A number of studies have suggested that antidepressants such as selective serotonin reuptake inhibitors may increase a risk of developing harmful cardiac adverse event such as QT interval prolongation. In fact, the US Food and Drug Administration (FDA) consecutively gave safety warnings to healthcare professionals that the use of citalopram may be associated with QT interval prolongation in 2011 and 2012. Despite the fact that citalopram has been one of the most acceptable antidepressants worldwide, concerns on citalopram about cardiac safety issues have become apparent to clinicians after the FDA warning. However, a recent cohort study raises some practical questions about the FDA warnings on the use of citalopram and may also provide clinicians with a good guidance for prudent use of citalopram in clinical practice.
多项研究表明，选择性 5-羟色胺再摄取抑制剂（SSRIs）等抗抑郁药可能会增加发生 QT 间期延长等有害心脏不良事件的风险。事实上，美国食品和药物管理局（FDA）在 2011 年和 2012 年连续向医疗保健专业人员发出安全警告，称使用西酞普兰可能与 QT 间期延长有关。尽管西酞普兰是全球最可接受的抗抑郁药之一，但在 FDA 发出警告后，临床医生对西酞普兰的心脏安全性问题的担忧已经显而易见。然而，最近的一项队列研究对 FDA 关于使用西酞普兰的警告提出了一些实际问题，也可能为临床医生在临床实践中谨慎使用西酞普兰提供了良好的指导。
